Home › Leucemia linfoblastica acuta › New York › New York City
Studi clinici su Leucemia linfoblastica acuta a New York City, NY
23 studi su Leucemia linfoblastica acuta cercano partecipanti presso sedi a New York City e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
In reclutamentoFase 1
- Memorial Sloan Kettering Cancer Center, New York
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
In reclutamentoFase 2
- Memorial Sloan Kettering Cancer Center -- Pediatrics, New York
Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children
In reclutamentoStudio osservazionale
- Columbia University Medical Center, New York
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
In reclutamentoFase 1/2
- Montefiore Medical Center, New York
Cord Blood Transplant in Adults With Blood Cancers
In reclutamentoFase 2
- Memorial Sloan Kettering Cancer Center, New York
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
In reclutamentoFase 1
- Memorial Sloan Kettering Cancer Center, New York
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
In reclutamentoFase 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
In reclutamentoFase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of CTD402 in T-ALL/LBL Patients
In reclutamentoFase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
In reclutamentoFase 1/2
- Research Site, New York
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
In reclutamentoStudio osservazionale
- New York University Langone Medical Center, New York
- New York Presbyterian Hospital at Cornell, New York
- Mount Sinai Medical Center - New York, New York
- e altri 3
A Study of Revumenib and Mezigdomide in People With Leukemia
In reclutamentoFase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
In reclutamentoFase 1/2
- Memorial Sloan Kettering Cancer Center, New York
European Prospective Investigation Into Childhood Cancer
In reclutamentoStudio osservazionale
- Columbia University Irving Medical Center, New York
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
In reclutamentoFase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
In reclutamentoFase 2
- Memorial Sloan Kettering, New York
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
In reclutamentoFase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
In reclutamentoFase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
In reclutamentoFase 1
- Memorial Sloan Kettering Cancer Center, New York
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
In reclutamento
- Columbia University Medical Center, New York
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
In reclutamentoFase 1
- Memorial Sloan Kettering Cancer Center, New York
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
In reclutamentoFase 1
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
Studi su Leucemia linfoblastica acuta in altre città
- Houston, TX28 studi
- Seattle, WA21 studi
- Baldwin Park, CA21 studi
- Chicago, IL20 studi
- Atlanta, GA19 studi
- Memphis, TN16 studi
- Washington, DC16 studi
- Philadelphia, PA16 studi
- Boston, MA15 studi
- Los Angeles, CA14 studi
- Mountain View, CA13 studi
- Durham, NC13 studi
Altri studi a New York City
- Cancro al seno136 studi
- Cancro del polmone non a piccole cellule121 studi
- Cancro (tutti i tipi)109 studi
- Cancro alla prostata103 studi
- Cancro metastatico93 studi
- Cancro colorettale78 studi
- Cancro ovarico69 studi
- Cancro ai polmoni60 studi
- Mieloma multiplo60 studi
- Cancro pancreatico60 studi
- Cancro dell'endometrio52 studi
- Leucemia mieloide acuta51 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.